Wendel Jacqueline S, Ye Lei, Zhang Pengyuan, Tranquillo Robert T, Zhang Jianyi Jay
1 Department of Biomedical Engineering, University of Minnesota , Minneapolis, Minnesota.
Tissue Eng Part A. 2014 Apr;20(7-8):1325-35. doi: 10.1089/ten.TEA.2013.0312. Epub 2014 Feb 6.
Cell therapies have emerged as a promising treatment for the prevention of heart failure after myocardial infarction (MI). This study evaluated the capacity of an aligned, fibrin-based, stretch-conditioned cardiac patch consisting of either the native population or a cardiomyocyte (CM)-depleted population (i.e., CM+ or CM- patches) of neonatal rat heart cells to ameliorate left ventricular (LV) remodeling in the acute-phase postinfarction in syngeneic, immunocompetent rats. Patches were exposed to 7 days of static culture and 7 days of cyclic stretching prior to implantation. Within 1 week of implantation, both patches became vascularized, and non-CMs began migrating from CM+ patches. By week 4, patches had been remodeled into collagenous tissue, and live, elongated, donor CMs were found within grafted CM+ patches. Significant improvement in cardiac contractile function was seen with the administration of the CM+ patch (ejection fraction increased from 35.1% ± 4.0% for MI only to 58.8% ± 7.3% with a CM+ patch, p<0.05) associated with a 77% reduction in infarct size (61.3% ± 7.9% for MI only, 13.9% ± 10.8% for CM+ patch, p<0.05), and the elimination of LV free-wall thinning. Decreased infarct size and reduced wall thinning also occurred with the administration of the CM- patch (infarct size 36.9% ± 10.2%, LV wall thickness: 1058.2 ± 135.4 μm for CM- patch, 661.3 ± 37.4 μm for MI only, p<0.05), but without improvements in cardiac function. Approximately 36.5% of the transplanted CMs survived at 4 weeks; however, they remained separated and electrically uncoupled from the host myocardium by a layer of CM-free tissue, which suggests that the benefits of CM+ patch transplantation resulted from paracrine mechanisms originating from CMs. Collectively, these observations suggest that the transplantation of CM-containing engineered heart tissue patches can lead to dramatic improvements in cardiac function and remodeling after acute MI.
细胞疗法已成为预防心肌梗死(MI)后心力衰竭的一种有前景的治疗方法。本研究评估了一种由新生大鼠心脏细胞的天然群体或心肌细胞(CM)缺失群体(即CM+或CM-贴片)组成的、排列整齐、基于纤维蛋白、经拉伸处理的心脏贴片改善同基因、具有免疫活性大鼠梗死急性期左心室(LV)重塑的能力。贴片在植入前先进行7天的静态培养和7天的循环拉伸。植入后1周内,两种贴片都实现了血管化,非CMs开始从CM+贴片中迁移出来。到第4周时,贴片已重塑为胶原组织,并且在移植的CM+贴片中发现了存活的、伸长的供体CMs。给予CM+贴片后,心脏收缩功能有显著改善(射血分数从仅MI组的35.1%±4.0%增加到CM+贴片组的58.8%±7.3%,p<0.05),梗死面积减少77%(仅MI组为61.3%±7.9%,CM+贴片组为13.9%±10.8%,p<0.05),并且左心室游离壁变薄现象消除。给予CM-贴片后也出现梗死面积减小和壁变薄减轻的情况(梗死面积为36.9%±10.2%,CM-贴片组左心室壁厚度:1058.2±135.4μm,仅MI组为661.3±37.4μm,p<0.05),但心脏功能没有改善。约36.5%的移植CMs在4周时存活;然而,它们仍被一层无CM组织分隔开,并且与宿主心肌电不偶联,这表明CM+贴片移植的益处源于CMs产生的旁分泌机制。总体而言,这些观察结果表明,移植含CM的工程化心脏组织贴片可使急性心肌梗死后的心脏功能和重塑得到显著改善。